Resultados de Búsqueda
It is recommended to consider taking a swab for microbiological testing from people with cellulitis or erysipelas to guide treatment, but only if the skin is broken and: there is a penetrating injury ...
NICE
National Institute for Health and Clinical Excellence (NICE
.
ver más ... 2019It is recommended, to ensure that cellulitis and erysipelas are treated appropriately, exclude other causes of skin redness such as: an inflammatory reaction to an immunisation or an insect bite or ...
NICE
National Institute for Health and Clinical Excellence (NICE
.
ver más ... 2019Risankizumab is recommended as an option for treating plaque psoriasis in adults, only if: the disease is severe, as defined by a total PASI of 10 or more and a DLQI of more than 10 and the disease ...
NICE
National Institute for Health and Clinical Excellence (NICE
Stop risankizumab treatment at 16 weeks if the psoriasis has not responded adequately. An adequate response is defined as: - a 75% reduction in the PASI score (PASI 75) from when treatment started or - a 50% reduction in the PASI score (PASI 50) and a 5‑point reduction in DLQI from when treatment started. If patients and their clinicians consider risankizumab to be one of a range of suitable treatments, including guselkumab, secukinumab and ixekizumab, the least expensive should be chosen ...
ver más ... 2019Certolizumab pegol is recommended as an option for treating plaque psoriasis in adults, on determined conditions.
NICE
National Institute for Health and Clinical Excellence (NICE
Certolizumab pegol is recommended as an option for treating plaque psoriasis in adults, only if: - the disease is severe, as defined by a total Psoriasis Area and Severity Index (PASI) of 10 or more and a Dermatology Life Quality Index (DLQI) of more than 10 and - the disease has not responded to other systemic treatments, including ciclosporin, methotrexate and phototherapy, or these options are contraindicated or not tolerated and - the lowest maintenance dosage of certolizumab pegol is used ...
ver más ... 2019It is recommended Tildrakizumab as an option for treating plaque psoriasis in adults, only if: the disease is severe, as defined by a total (PASI) of 10 or more and a (DLQI) of more than 10 and the ...
NICE
National Institute for Health and Clinical Excellence (NICE
Consider stopping tildrakizumab between 12 weeks and 28 weeks if there has not been at least a 50% reduction in the PASI score from when treatment started. Stop tildrakizumab at 28 weeks if the psoriasis has not responded adequately. An adequate response is defined as: - a 75% reduction in the PASI score (PASI 75) from when treatment started or - a 50% reduction in the PASI score (PASI 50) and a 5‑point reduction in DLQI from when treatment started. If patients and their clinicians ...
ver más ... 2019